$0.0120
At close: Dec 18, 12:55 PM EDT
Comments
Loading...
Bellerophon Therapeutics Inc Com (New) Analyst Ratings and Price Targets | OTC:BLPH | Benzinga
Bellerophon Therapeutics Inc Com (New) has a consensus price target of $2 based on the ratings of 2 analysts. The high is $2 issued by HC Wainwright & Co. on June 6, 2023. The low is $2 issued by HC Wainwright & Co. on June 6, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Laidlaw & Co. on June 6, 2023, May 17, 2023, and May 9, 2023, respectively. With an average price target of $22.33 between HC Wainwright & Co., HC Wainwright & Co., and Laidlaw & Co., there's an implied 186011.11% upside for Bellerophon Therapeutics Inc Com (New) from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Bellerophon Therapeutics Inc Com (New)
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/06/2023 | Buy Now | 16566.67% | HC Wainwright & Co. | Andrew Fein57% | $30 → $2 | Maintains | Buy | Get Alert |
| 06/06/2023 | Buy Now | — | Laidlaw & Co. | Yale Jen25% | — | Downgrade | Buy → Hold | Get Alert |
| 05/17/2023 | Buy Now | 249900% | HC Wainwright & Co. | Andrew Fein57% | → $30 | Reinstates | Buy → Buy | Get Alert |
| 05/09/2023 | Buy Now | 291566.67% | Laidlaw & Co. | Yale Jen25% | → $35 | Initiates | → Buy | Get Alert |
| 04/04/2023 | Buy Now | 249900% | HC Wainwright & Co. | Andrew Fein57% | → $30 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Bellerophon Therapeutics Inc Com (New) (BLPH) stock?
The latest price target for Bellerophon Therapeutics Inc Com (New) (OTC:BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 16566.67% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bellerophon Therapeutics Inc Com (New) (BLPH)?
The latest analyst rating for Bellerophon Therapeutics Inc Com (New) (OTC:BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics Inc Com (New) maintained their buy rating.
When was the last upgrade for Bellerophon Therapeutics Inc Com (New) (BLPH)?
There is no last upgrade for Bellerophon Therapeutics Inc Com (New)
When was the last downgrade for Bellerophon Therapeutics Inc Com (New) (BLPH)?
The last downgrade for Bellerophon Therapeutics Inc Com (New) happened on June 6, 2023 when Laidlaw & Co. changed their price target from N/A to N/A for Bellerophon Therapeutics Inc Com (New).
When is the next analyst rating going to be posted or updated for Bellerophon Therapeutics Inc Com (New) (BLPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics Inc Com (New), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics Inc Com (New) was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.
Is the Analyst Rating Bellerophon Therapeutics Inc Com (New) (BLPH) correct?
While ratings are subjective and will change, the latest Bellerophon Therapeutics Inc Com (New) (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics Inc Com (New) (BLPH) is trading at is $0.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
